Latest News
Upcoming Event
Latest Financial Results
Latest Annual Filing
For Fiscal Year Ending Mar 31, 2024
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Grace Therapeutics is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal subarachnoid hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.
The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTx-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTx-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTx-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.
IR Contacts
Headquarters
Grace Therapeutics, Inc.
103 Carnegie Center
Suite 300
Princeton, NJ 08540
T: 450-687-2262
info@GraceTherapeutics.com
Investor Relations
LifeSci Advisors
Mike Moyer
Managing Director
T: 617-308-4306
mmoyer@lifesciadvisors.com
Transfer Agent
Computershare Trust Company NA
PO Box 43006
Providence, RI 02940-3006
T: 800-736-3001
https://www-us.computershare.com/Investor